Safety of biologic therapies for the treatment of juvenile idiopathic arthritis

Expert Opinion on Drug Safety

Volumn 14, Issue 7, 2015, Pages 1111-1126

  Horneff, Gerd ^a  

^a Centre of Paediatric Rheumatology Department of General Paediatrics Asklepios Clinic Sankt Augustin   (Germany)

Author keywords

Abatacept; Adalimumab; Etanercept; Infliximab; Juvenile idiopathic arthritis; Safety; TNF inhibitors; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CANAKINUMAB; ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; APPENDICITIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BACTERIAL SUPERINFECTION; BIOLOGICAL THERAPY; BRONCHITIS; CANDIDIASIS; CELLULITIS; CERVICAL SPINE DISLOCATION; CHICKENPOX; CONCUSSION; CONJUNCTIVITIS; COUGHING; COXITIS; CROHN DISEASE; CYTOPENIA; DEMYELINATING DISEASE; DENTAL CARIES; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIGASTRIC PAIN; FLU LIKE SYNDROME; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HERPES SIMPLEX; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INFUSION RELATED REACTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MACROPHAGE ACTIVATION SYNDROME; MENINGOCOCCEMIA; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL CHEST PAIN; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OTITIS; PERITONITIS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PSYCHOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL INFECTION; T LYMPHOCYTE ACTIVATION; THYROID CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VASCULITIS; VIRAL GASTROENTERITIS; VIRAL UPPER RESPIRATORY TRACT INFECTION; ARTHRITIS, JUVENILE; CHILD; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; POSTMARKETING SURVEILLANCE; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL THERAPY; CHILD; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETANERCEPT; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 84931829640     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1042453     Document Type: Review

References (62)

1. Berntson L, Andersson Gare B, Fasth A, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 2003;30:2275-82
2. Danner S, Sordet C, Terzic J, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006;33:1377-81
3. Peterson LS, Mason T, Nelson AM, et al. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing Arthritis Rheum 1996;39:1385-90
4. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10:3049-60
5. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:465-82.
6. Lovell DJ, Giannini EH, Reiff A, et al. for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
7. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or Etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7
8. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22
9. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20
10. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label Etanercept on extended oligoarticular juvenile idiopathic arthritis. enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the Clipper study. Ann Rheum Dis 2014;73:1114-22.
11. Horneff G, Foeldvari I, Minden K, et al. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 2011;50(1):230-6
12. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24.
13. McCroskery P, Wallace CA, Lovell DJ, et al. Summary of worldwide pediatric malignancies reported after exposure to Etanercept. Pediatr Rheumatol Online J 2010;8:18
14. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of Etanercept in children with polyarticularcourse juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94
15. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504
16. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22
17. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2004;63:1638-44
18. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of Etanercept and methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
19. Horneff G, Foeldvari I, Minden K, et al. [10 years experience in the German JIA Etanercept Registry-lessons from changing patient populations]. Arthritis Rheum 2011;31:334-42
20. Prince FH, Twil M, Ten Cate R, et al. Long-term follow-up on effectiveness and safety of Etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41
21. Southwood TR, Foster HE, Davidson JE, et al. Duration of Etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011;50:189-95
22. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of Etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804
23. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
24. Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol 2014;41(12):2459-65
25. Nimmrich S, Horneff G. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Rheumatol Int 2015;35(3):465-70
26. Barthel D, Horneff G. Inflammatory bowel disease in juvenile idiopathic arthritis patients upon biologics [abstract]. Arthritis Rheum 2013;65(Suppl 10):268
27. Zuber Z, Rutkowska-Sak L, Postepski J, et al. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit 2011;17:SR35-42
28. Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012;14(5):R230.
29. Burgos-Vargas R, Tse SML, Horneff G, et al. A double-blind, placebo-controlled, multicenter study of the efficacy and safety of adalimumab in pediatric patients with enthesitis-related arthritis. In press
30. Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol 2014;33(10):1433-41
31. Horneff G, Ruperto N, Wallace C, et al. Long term safety and effectiveness of Adalimumab in children with moderately to severly active polyarticular or polyarticular course Juvenile Idiopathic Arthritis. Ann Rheum Dis 2014;73(Suppl 2):61-2
32. Schmeling H, Minden K, Foeldvari I, et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 2014;66(9):2580-9.
33. Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTEJIA): a multicentre randomised openlabel clinical trial. Ann Rheum Dis 2011;70(9):1605-12.
34. Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, et al. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years. J Rheumatol 2014;41(7):1409-15
35. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91
36. Ruperto N, Lovell DJ, Quartier P. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802
37. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012;22(1):109-15
38. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2014. [Epub ahead of print].
39. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006
40. Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 2014;41(4):759-67
41. Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathiy arthritis. N Engl J Med 2012;367:2385-95.
42. Horneff G, Huppertz HI, Ganser G, et al. Drug safety in treatment of juvenile idiopathic arthritis (JIA): biologic therapy compared with MTX. Arthritis Rheum 2014;66:Suppl:S121
43. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juv idiopathic arthritis. N Engl J Med 2012;367(25):2396-406.
44. Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with Etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;3850-5
45. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2014. [Epub ahead of print]
46. Horneff G, Becker I. On behalf of German and Austrian Collaborative BIKER study group. Serious infections in Juvenile Idiopathic Arthritis patients upon TNF inhibitors depend on disease activity. Arthritis Rheum 2014;73(suppl 2):114-5
47. Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(8):2773-80.
48. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301(7):737-44
49. van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with Etanercept. J Rheumatol 2011;38:1441-6
50. Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with Etanercept: a French retrospective study. Rheumatology (Oxford) 2010;49:1694-8
51. Peyrin-Biroulet L, Deltenre P, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
52. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomised, double-blind, placebocontrolled trial. Gastroenterology 2001;121:1088-94
53. Heiligenhaus A, Heinz C, Edelsten C, et al. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013;21(3):180-91
54. Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013;21(1):12-20
55. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of Etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53(1):18-23
56. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63(4):612-18
57. Anink J, Otten MH, Gorter SL, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab Rheumatology (Oxford) 2013;52(9):1674-9
58. Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006;149(6):833-6
59. Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010;62(12):3776-82.
60. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(4):1263-71.
61. Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008;280-8 doi: 10.1182/asheducation-2008.1.280
62. Cron R, Beukelman T. Guilt by association-what is the true risk of malignancy in children treated with etanercept for JIA Pediatr Rheumatol Online J 2010;8:23